IRD
$4.80
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It d...
Recent News
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating
Opus Genetics, Inc. (NASDAQ:IRD) is among the 11 Fastest Growing Penny Stocks to Buy Right Now. On March 2, 2026, BTIG raised the price target on Opus Genetics, Inc. (NASDAQ:IRD) to $12 from $7 and maintained a Buy rating. BTIG said the company’s investment story appears to be gaining momentum after the initial BEST1 correction […]
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -31.21% and +47.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of -75.51% and -94.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 0.7% and the S
Update: Opus Genetics Shares Rise After Announcement of $25 Million Private Placement
(Updates to add stock move in the headline and the first paragraph.) Opus Genetics (IRD) shares